← Back to Search

Intrahepatic Cholangiocarcinoma (Validation) for Liver Tumors (ELUCIDATE Trial)

N/A
Recruiting
Led By Ajay Goel, PhD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

ELUCIDATE Trial Summary

It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.

Eligible Conditions
  • Liver Tumors
  • Liver Cancer
  • Intrahepatic Cholangiocarcinoma
  • Bile Duct Cancer

ELUCIDATE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Sensitivity
Secondary outcome measures
Proportion of correct predictions (true positives and true negatives) among the total number of cases (i.e., accuracy)
Specificity

ELUCIDATE Trial Design

4Treatment groups
Experimental Treatment
Group I: Intrahepatic Cholangiocarcinoma (Validation)Experimental Treatment1 Intervention
A cohort of patients with histologically confirmed intrahepatic cholangiocarcinoma (ICC)
Group II: Intrahepatic Cholangiocarcinoma (Training)Experimental Treatment1 Intervention
A cohort of patients with histologically confirmed intrahepatic cholangiocarcinoma (ICC)
Group III: Hepatocellular Carcinoma (Validation)Experimental Treatment1 Intervention
A cohort of patients with histologically confirmed hepatocellular carcinoma (HCC)
Group IV: Hepatocellular Carcinoma (Training)Experimental Treatment1 Intervention
A cohort of patients with histologically confirmed hepatocellular carcinoma (HCC)

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
565 Previous Clinical Trials
1,921,060 Total Patients Enrolled
Ajay Goel, PhDPrincipal InvestigatorCity of Hope Medical Center
6 Previous Clinical Trials
3,977 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
2024. "An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06342414.
All > Anaheim > Paid Studies Ventura
~267 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top